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Understanding the activation mechanism of Cys loop ion
channel receptors is key to understanding their physiological
and pharmacological properties under normal and pathological
conditions. The ligand-binding domains of these receptors
comprise inner and outer -sheets and structural studies indi-
cate that channel opening is accompanied by conformational
rearrangements inboth-sheets. Inanattempttoresolve ligand-
dependent movements in the ligand-binding domain, we
employed voltage-clamp fluorometry on1 glycine receptors to
compare changes mediated by the agonist, glycine, and by the
antagonist, strychnine. Voltage-clamp fluorometry involves
labeling introduced cysteines with environmentally sensitive
fluorophores and inferring structural rearrangements from
ligand-induced fluorescence changes. In the inner -sheet, we
labeled residues in loop 2 and in binding domain loops D and E.
At each position, strychnine and glycine induced distinct maxi-
mal fluorescence responses. The pre-M1 domain responded
similarly; at each of four labeled positions glycine produced a
strong fluorescence signal, whereas strychnine did not. This
suggests that glycine induces conformational changes in the
inner -sheet and pre-M1 domain that may be important for
activation, desensitization, or both. In contrast, most labeled
residues in loops C and F yielded fluorescence changes identical
in magnitude for glycine and strychnine. A notable exception
wasH201C in loopC.This labeled residue respondeddifferently
to glycine and strychnine, thus underlining the importance of
loopC in liganddiscrimination. These results provide an impor-
tant step toward mapping the domains crucial for ligand dis-
crimination in the ligand-binding domain of glycine receptors
and possibly other Cys loop receptors.
Glycine receptor (GlyR)3 chloride channels are pentameric
Cys loop receptors that mediate fast synaptic transmission in
the nervous system (1, 2). This family also includes nicotinic
acetylcholine receptors (nAChRs), -aminobutyric acid type A
and typeC receptors, and serotonin type 3 receptors. Individual
subunits comprise a large ligand-binding domain (LBD) and a
transmembrane domain consisting of four-helices (M1–M4).
The LBD consists of a 10-strand -sandwich made of an inner
-sheet with six strands and an outer -sheet with four strands
(3). The ligand-binding site is situated at the interface of adja-
cent subunits and is formedby loopsA–C fromone subunit and
loops D–F from the neighboring subunit (3).
The activation mechanism of Cys loop receptors is currently
the subject of intense investigation because it is key to under-
standing receptor function under normal and pathological con-
ditions (4, 5). Based on structural analysis of Torpedo nAChRs,
Unwin and colleagues (6, 7) originally proposed that agonist
binding induced the inner -sheet to rotate, whereas the outer
-sheet tilted slightly upwards with loop C clasping around the
agonist. These movements were thought to be transmitted to
the transmembrane domain via a differentialmovement of loop
2 (1-2) and loop 7 (6-7) (both part of the inner -sheet)
and the pre-M1 domain (which is linked via a -strand to the
loop C in the outer sheet). The idea of large loop Cmovements
accompanying agonist binding is supported by structural and
functional data (3, 8–13). However, a direct link between loop
C movements and channel gating has proved more difficult to
establish. Although computational modeling studies have sug-
gested that this loop may be a major component of the channel
opening mechanism (14–18), experimental support for this
model is not definitive. Similarly, loop F is also thought tomove
upon ligand binding, although there is as yet no consensus as to
whether these changes represent local or global conformational
changes (11, 19–21). Recently, a comparison of crystal struc-
tures of bacterial Cys loop receptors in the closed and open
states revealed that although both the inner and outer -sheets
exhibit different conformations in closed and open states, the
pre-M1 domain remains virtually stationary (22, 23). It is there-
fore relevant to question whether loop C, loop F, and pre-M1
movements are essential for Cys loop receptor activation.
Strychnine is a classical competitive antagonist of GlyRs (24,
25), and to date there is no evidence that it can produce LBD
structural changes. In this studywe use voltage-clamp fluorom-
etry (VCF) to compare glycine- and strychnine-induced con-
formational changes in the GlyR loops 2, C, D, E, and F and the
pre-M1 domain in an attempt to determinewhether they signal
ligand-binding events, local conformational changes, or con-
formational changes associated with receptor activation.
In a typical VCF experiment, a domain of interest is labeled
with an environmentally sensitive fluorophore, and current and
fluorescence are monitored simultaneously during ligand
application. VCF is ideally suited for identifying ligand-specific
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conformational changes because it can report on electrophysi-
ologically silent conformational changes (26), such as those
induced by antagonists. Indeed, VCF has recently provided val-
uable insights into the conformational rearrangements of vari-
ous Cys loop receptors (19, 21, 27–33).
EXPERIMENTAL PROCEDURES
Chemicals—Glycine (Ajax Finechem, Seven Hills, Australia)
was dissolved in water and stored at 4 °C. Strychnine (Sigma-
Aldrich) was dissolved inMe2SO (Sigma-Aldrich) and stored at
20 °C. Sulforhodamine methanethiosulfonate (MTSR) and
2-((5(6)-tetramethylrhodamine) carboxylamino)ethyl meth-
anethiosulfonate (MTS-TAMRA) were purchased from
Toronto Research Chemicals (North York, Canada). Alexa
Fluor 546C5maleimide (AF546) and tetramethylrhodamine-6-
maleimide (TMRM) were purchased from Invitrogen. MTSR,
MTS-TAMRA, and TMRM were dissolved in Me2SO and
stored at20 °C.AF546was dissolved inwater on the day of the
experiment and stored on ice for up to 6 h.
Molecular Biology—Human GlyR 1 cDNA was subcloned
into the pGEMHEvector. All of the constructs generated in this
studyweremade on the1GlyRC41Abackground to eliminate
the only uncross-linked extracellular cysteine. QuikChange
(Stratagene, La Jolla, CA) was used to generate all of the cys-
teine mutants used in this study. Automated sequencing of the
entire coding sequence confirmed successful incorporation of
the mutations. Capped mRNA for oocyte injection was gener-
ated using mMessage mMachine (Ambion, Austin, TX).
Oocyte Preparation, Injection, and Labeling—Oocytes from
female Xenopus laevis (Xenopus Express, France) were pre-
pared as previously described (31) and injected with 10 ng of
mRNA. The oocytes were then incubated at 18 °C for 3–10 days
in an incubation solution containing 96 mM NaCl, 2 mM KCl, 1
mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 0.6 mM theophylline,
2.5 mM pyruvic acid, 50g/ml gentamycin (Cambrex Corpora-
tion, East Rutherford, NJ), pH 7.4.
Fluorophore Labeling—On the day of recording, the oocytes
were transferred into ND96 (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.4) containing 10–20
M of the dye. Typical labeling times were 30 s for MTSR and
MTS-TAMRA (on ice), 30 min for TMRM (on ice), or 45 min
for AF546 (at room temperature). The oocytes were then thor-
oughly washed and stored in ND96 for up to 6 h on ice before
recording. All four sulfhydryl-reactive fluorophores employed
in this study respond with an increase in quantum efficiency as
the hydrophobicity of their environment is increased (27, 28,
30, 34). Each cysteine mutant was incubated with all four flu-
orophores in turn, and the one yielding the largest fluorescence
change (F) upon agonist application was analyzed. Fig. 1
shows a model of the GlyR LBD showing the positions of suc-
cessfully labeled residues. Because wild typeGlyRs never exhib-
ited a F or a change in electrophysiological properties follow-
ing fluorophore incubation (see Table 1), we can rule out
nonspecific effects of the labels.
VCF and Data Analysis—The experimental set up has
recently been described in detail (31). In brief, an inverted flu-
orescence microscope was equipped with a high-Q tetrameth-
ylrhodamine isothiocyanate filter set (Chroma Technology,
Rockingham, VT), a Plan Fluor 40 objective lens (Nikon
Instruments, Kawasaki, Japan), and a PhotoMax 200 photo-
diode (Dagan Corporation, Minneapolis, MN) with a xenon
lamp as light source (Sutter Instruments, Novato, CA). The
recording chamber is described in detail in Ref. 28. The cells
were voltage-clamped at40 mV, and currents were recorded
with a Gene Clamp 500B amplifier (Axon Instruments, Union
City, CA). Current and fluorescence traceswere acquired at 200
Hz via a Digidata 1322A interface using Clampex 9.2 software
(Axon Instruments). Fluorescence signals were digitally filtered
at 1–2 Hz with an eight-pole Bessel filter for analysis and dis-
play. Half-maximal concentrations (EC50) and Hill coefficient
(nH) values for ligand-induced activation of current and fluo-
rescence were obtained using the Hill equation fitted with a
nonlinear least squares algorithm (SigmaPlot 9.0, Systat Soft-
ware, Point Richmond, CA). All of the results are expressed as
the means S.E. of three or more independent experiments.
Spectral Analysis—The spectral analysis methodology has
previously been explained in detail (31). In brief, the photo-
diode was replaced by a MicroSpec 2150i spectrometer (Acton
Research Corporation, Acton, MA) coupled to an ORCA-ER
CCD camera (Hamamatsu, Hamamatsu City, Japan) and oper-
ated using SpectraPro Monochromator Software (Acton
Research Corporation, Acton, MA). For excitation, a HQ535/
50 filter was used in combination with a Q565LP dichroic
mirror (Chroma Technology, Rockingham, VT) and no emis-
sion filter. The region of interest was aligned with the slit of the
spectrometer and reflected onto the grating (300 g/mm;
500-nm blaze). The extracted spectrum was imaged on the
ORCA-ERCCDusingMetaMorph 6.2 (Universal ImagingCor-
poration, Downington, PA). The x axis of the resulting “spectral
image” represents the wavelength dimension, whereas the y
axis represents the one-dimensional spatial dimension of the
slit. The results from six oocytes were averaged and not sub-
jected to further filtering.
RESULTS
Loop E—The loop E domain in the inner -sheet forms a
-strand that lines the agonist-binding site (3). VCF studies
showed that loop E residues of GABAA receptor subunits
report structural rearrangements that are correlatedwith chan-
nel activation (27, 30). The corresponding GlyR mutants,
L127C and R122C, were both investigated in the present study.
The location of L127C is indicated in Fig. 1. The L127C muta-
tion resulted in a large decrease in glycine sensitivity that
decreased further following labelingwithMTS-TAMRA (Table
1). The MTS-TAMRA-labeled L127C mutant GlyR responded
with large (50%) F increases during glycine-mediated acti-
vation (Fig. 2A). As previously suggested (30, 35), this increased
fluorescence is consistent with the idea of a ligand-induced clo-
sure of the agonist-binding site. Consistent with both previous
studies (27, 30), we found the glycine sensitivity of the change in
current (I) and F responses to be identical (Fig. 2, A and B,
andTable 1). Note that the deactivation kinetics often appeared
different for F and I signals from the same oocyte (Fig. 2A).
Because current was recorded from the entire oocyte, whereas
fluorescence recorded from a small membrane portion, these
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effects may have been due to nonuniform solution exchange
profiles around the oocyte.
Application of the competitive antagonist strychnine in the
absence of glycine also evoked large F signals (Fig. 2C). These
signals exhibited a mean EC50 of 280  22 nM, an nH of 1.1 
0.1, and aFmax of 147 43% (n 5 cells). Because the strych-
nine Fmax was three times greater than that produced by a
saturating glycine concentration (Fig. 2D), it is likely that the
two compounds induced distinct structural changes. To further
test this possibility, we performed a spectroscopic analysis of
the fluorescence signal before, during, and after the application
of glycine or strychnine (Fig. 2E). We found that glycine appli-
cation increased the quantum yield but did not significantly
shift the emission peak (compared with the emission peak
before glycine application). However, strychnine application
produced both an increase in quantum yield and a4-nm blue
shift in the emission spectrum (Fig. 2F). This highly significant
difference (p 0.001) suggests that glycine-induced conforma-
tional changes are mainly evoked by dequenching, whereas
strychnine-induced movements also result in an increased hy-
drophobicity in the fluorophore environment. This finding
supports the idea of ligand-specific conformational changes at
L127C.
Labeling with MTSR produced similar results to MTS-
TAMRA, although AF546 and TMRM produced no significant
glycine-dependent F (n  3–5 cells each). Although the
AF546-labeled E122C in the GABAA receptor 2 subunit pro-
duces F responses that correlate well with channel activation
(30), the corresponding GlyR mutant (R122C) did not give rise
to a significant F with any of the four fluorophores.
Loop D—Like loop E, loop D is a -strand on the inner
-sheet. A portion of this strand contributes to the comple-
mentary () side of the GlyR-binding pocket (36). Because
Phe63 and Arg65 in loop D are important residues for ligand
binding (36, 37), we reasoned that the adjacent residues on the
same side of the -strand, Q67C and N69C, may report on
conformational rearrangements during agonist and antagonist
binding. Introduction of the Q67C mutation led to a minor
increase in the current EC50, which increased further after
incubation with MTS-TAMRA (Table 1). Glycine application
to Q67C-injected oocytes labeled with MTS-TAMRA evoked
FIGURE 1.Model of the LBD, based on AChBP bound to carbomylcholine
(Protein Data Bank code 1uv6, model generated with PyMOL 0. 99,
DeLano Scientific LLC, PaloAlto, CA). The inner-sheet is shown in red, the
outer -sheet is in blue, and the connecting loops are displayed in gray. The
black balls represent approximate locations of residues labeled in loops flank-
ing the outer-sheet (V178C, A179C, and G181C in loop F; H201C andN203C
in loop C; and E217C and Q219C in the pre-M1 domain). G221C and M227C
are not shown because they are not present in the AChBP structure. The
yellow balls show approximate location of residues labeled in the inner
-sheet (L127C in loop E, Q67C in loop D, and A52C in loop 2).
TABLE 1
Summary of results for glycine-evoked current and fluorescence
recordings
Displayed are the values for half-maximal activation (EC50), Hill coefficient (nH),
number of experiments (n), and maximal current and fluorescence responses (Imax
and  Fmax, respectively). All of the results for fluorescence are shown in bold type.
Construct EC50 nH I or Fmax n
M A or %
WT
WT I unlabeled 15.5 0.3 2.6 0.1 8.3 0.4 3
WT I MTS-TAMRA 15.6 0.4 2.7 0.1 7.9 0.2 3
WT I TMRM 15.9 0.4 2.7 0.1 6.6 0.5 3
WT I AF546 16.3 0.3 2.5 0.1 6.8 0.9 3
Loop E
L127C I unlabeled 1020 20 2.4 0.2 7.3 0.3 3
L127C I MTS-TAMRA 4950 180a 2.4 0.2 7.7 0.8 7
L127C F MTS-TAMRA 6070 240b 1.8 0.1b 46.7 7.1 7
Loop D
Q67C I unlabeled 44.1 1.2 2.7 0.1 7.2 0.3 3
Q67C I MTS-TAMRA 63.1 0.6a 2.9 0.1 7.2 0.5 3
Q67C F MTS-TAMRA 1180 50b 1.7 0.1b 18.0 0.6 3
Loop F
V178C I unlabeled 47.4 1.0 2.6 0.1 12.3 1.8 5
V178C I AF546 40.7 0.1 2.6 0.1 10.3 2.3 8
V178C F AF546 313 20b 1.3 0.1b 12.6 0.6 9
A17C I unlabeled 83.6 5.0 2.6 0.5 8.0 0.6 4
A179C I MTS-TAMRA 135 9a 1.7 0.2a 8.4 0.3 4
A179C F MTS-TAMRA 642 117b 1.5 0.4 2.2 0.6 3
G181C unlabeled 29.3 0.8 2.8 0.3 7.6 0.4 5
G181C MTSR 39.8 1.3 1.9 0.1a 9.9 2.1 5
G181C F MTSR 503 65b 1.3 0.2b 11.6 2.7 6
Loop C
H201C I unlabeled 17.9 0.6 2.9 0.2 10.3 1.0 5
H201C I MTS-TAMRA 16.3 0.6 2.9 0.2 9.3 0.8 6
H201C F MTS-TAMRA 126 3b 2.1 0.1b 10.2 1.0 5
N203C I unlabeled 25.9 0.2 3.0 0.1 6.6 0.5 3
N203C I MTS-TAMRA 45.7 1.2a 3.0 0.2 6.9 0.2 6
N203C F MTS-TAMRA 526 25b 1.2 0.1b 44.3 5.9 6
Loop 2
A52C I unlabeled 18.5 0.1 3.2 0.1 7.8 0.2 3
A52C I MTS-TAMRA 17.4 0.1 3.0 0.1 7.7 0.2 4
A52C F MTS-TAMRA 201 10b 1.4 0.1b 8.6 1.1 4
Pre-M1
E217C I unlabeled 30.2 0.1 2.6 0.4 17.6 3.6 4
E217C I TMRM 27.1 0.1 3.2 0.4 17.0 0.6 3
E217C F TMRM 135 9.4b 1.9 0.2b 1.8 0.5 3
Q219C I unlabeled 20.9 0.9 2.6 0.2 8.3 0.4 8
Q219C I MTSR 9.2 0.2a 2.6 0.2 8.4 0.4 7
Q219C F MTSR 98.6 9.9b 1.5 0.2b 13.3 0.8 9
G221C I unlabeled 5.6 0.4 2.3 0.2 5.5 0.1 3
G221C I MTS-TAMRA 2.0 0.2a 1.8 0.3 2.9 0.3a 4
G221C F MTS-TAMRA 6.8 0.1b 1.8 0.1 16.3 0.9 4
M227C I unlabeled 28.7 0.1 2.9 0.1 7.8 0.8 3
M227C I AF546 13.1 0.1a 2.4 0.1a 6.5 0.5 3
M227C F AF546 226 24b 1.0 0.1b 3.5 0.3 3
a Significant difference to electrophysiological properties of unlabeled oocytes (Stu-
dent’s t test; p 0.05).
b Significant difference of fluorescence properties to electrophysiological properties
after labeling (Student’s t test; p 0.05).
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large ( 20%) fluorescence changes (Fig. 3A). The current EC50
was significantly lower than the fluorescence EC50, whereas nH
showed the opposite trend (Fig. 3B). Application of strychnine
led to dramatically larger F values than those induced by gly-
cine (Fmax 213 80%, EC50 1.4 0.1, nH 1.5 0.1, n
4) (Fig. 3, C and D), suggesting distinct conformations.
Attempts to label the adjacentN69C residuewere unsuccessful;
we observed robust currents but no change in glycine sensitivity
or a F after incubation with any of the four dyes (n  3–4
each).
Loop F—Loop F is an unstructured region located at the bot-
tom of the agonist-binding site (Fig. 1) (3, 11). A number of
studies have proposed this loop as an important element of the
Cys loop receptor gatingmechanism (21, 38–40), although one
VCF study has recently challenged this view (19). To determine
whether conformational rearrangements in GlyR loop F dis-
criminate between agonists and antagonists, we investigated
four consecutive mutants in this region: V178C, A179C,
D180C, and G181C. The V178C mutation produced a signifi-
cant but small increase in the glycineI EC50 (Table 1) that did
not change following incubation with any of the four fluoro-
phores. After incubation with AF546, oocytes injected with the
V178C mutant GlyR produced Fmax signals of10% (Fig. 4A
and Table 1). The glycine I EC50 was significantly lower than
that of F, with nH showing the opposite trend (Fig. 4, A and B,
and Table 1). As expected, the competitive antagonist strych-
nine did not produce a I but elicited a concentration-depend-
ent F of the same sign as glycine (Fig. 4C). Averaged from
seven oocytes, the strychnine concentration-response curve
was fitted by an EC50 of 127  9 nM, an nH of 1.6  0.2, and a
Fmax of 10.0  1.6%. Importantly, the Fmax values were vir-
tually identical for glycine and strychnine (Fig. 4D), suggesting a
similar structural rearrangement.
The A179C mutant GlyR exhibited a moderate (5-fold)
decrease in glycine sensitivity (Table 1). Labeling with MTS-
TAMRA further decreased the glycine sensitivity and gave rise
to small (2%) Fmax signals. Again, the I EC50 was signifi-
cantly lower than the F EC50, with the nH showing the oppo-
site trend (Table 1). No F was observed following incubation
of the adjacent D180C mutation with any of the fluorophores,
FIGURE 2.Glycine and strychnine induce distinct conformations around L127C in loop E. A, glycine-induced current (black) and fluorescence (red) traces
recorded from oocytes injected with L127C. B, averaged dose-response relationships for glycine. C, strychnine-induced current (black) and fluorescence (red)
responses at a saturating strychnine concentration. In this and subsequent figures, the horizontal bars denote the duration of glycine (gly) or strychnine (str)
application. D, comparison of maximal current (gray) and maximal fluorescence (red) responses for glycine and strychnine. The data normalized to mean
glycine values. *, p 0.0005. E, spectral emission from MTSR-labeled L127C oocytes before (gray) and during the application of glycine (black) or strychnine
(red) (average of six cells each). Note that the trace obtained after the application of both ligands is omitted for clarity, because it was identical to the trace
before the application of ligands (gray). F, normalized difference emission spectra recorded during application of glycine and strychnine. The spectra recorded
in theabsenceofglycinewere subtracted fromspectra recorded in thepresenceofglycine (black) and strychnine (red), respectively (the traceswerenormalized
to the strychnine response; average of six cells each). The arrows indicate the emission peak of glycine (black) and strychnine (red). Glycine showed no
significant shift in theemissionpeak comparedwith theemissionpeakbefore ligandapplication (0.10.2nm,n6).However, theemissionpeakduring
strychnine application was significantly (p 0.001) blue -shifted compared with the emission peak before ligand application ( 3.8 0.4 nm, n 6).
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although the current EC50 was significantly increased after
labeling with MTSR (D180C unlabeled: EC50 58.6 2.7 M,
nH 1.9 0.1, Imax 6.0 1.3 A; after labeling withMTSR:
EC50 98.8 0.1M, nH 2.3 0.5, Imax 6.9 0.1A; n
4 each).
MTSR labeling resulted in large (	10%) Fmax values at
G181C mutant GlyR (Fig. 4A). Again, the EC50 for I was sig-
nificantly lower than that for F, whereas the nH value was
significantly lower for F (Fig. 4, A and B, and Table 1). Fmax
induced by the antagonist strychnine did not vary from those
induced by agonists (Fig. 4, C and D). The mean strychnine
F concentration response, averaged from four oocytes,
yielded an EC50 of 208  25 nM, an nH of 1.2  0.1, and a
Fmax of 12.6  3.1%.
Loop C—Loop C is a relatively flexible domain that adopts an
extended conformation in the absence of agonist (10, 16, 41).
Upon agonist binding it is hypothesized to undergo a large
motion to cap the ligand-binding site (5, 6, 11, 42). This capping
motion has been suggested to serve as a trigger for channel
opening (5, 12, 15, 43), although to date there is little direct
experimental evidence for this. Importantly, structural studies
have suggested that loop C shows ligand-specific movements
(8, 9, 11), although a recent VCF study could neither entirely
prove or dismiss this hypothesis (27). We avoided investigating
FIGURE 3. Glycine and strychnine induce distinct conformations around Q67C in loop D. A, glycine-induced current (black) and fluorescence (red) traces
recorded from oocytes injected with Q67C. B, averaged dose-response relationships for glycine (gly). C, strychnine-induced current (black) and fluorescence
(red) responses at a saturating strychnine (str) concentration.D, comparisonofmaximal current (gray) andmaximal fluorescence (red) responses for glycine and
strychnine. Note the broken y axis. The data normalized to mean glycine values. *, p 0.0005
FIGURE 4. Glycine and strychnine induce similar conformational changes in loop F. A, glycine-induced current (black) and fluorescence (red) traces
recorded from oocytes injected with V178C (upper panel) or G181C (lower panel). B, averaged dose-response relationships for glycine (gly). C, strychnine-
induced current (black) and fluorescence (red) responses at a saturating strychnine (str) concentration. D, comparison of maximal current (gray) and maximal
fluorescence (red) responses for V178C (upper panel) and G181C (lower panel). The data are normalized to the mean glycine values. *, p 0.0005.
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loop C residues Lys200, Tyr202, Thr204, and Phe207 because they
are important ligand-binding residues (36, 37, 44, 45). Because
alanine mutations of the adjacent residues His201, Asn203, and
Lys206 have modest effects on agonist and antagonist binding
(45), we introduced cysteines individually at these positions.
Oocytes expressing the N203C mutant GlyR showed a signifi-
cant decrease in glycine sensitivity and robust F values after
labeling withMTS-TAMRA (Table 1 and Fig. 5A). As shown in
Fig. 5B and summarized in Table 1, the glycine I EC50 was
significantly lower than that for the F signal, and the F nH
was significantly decreased. When applied alone, strychnine
also produced large F signals (Fig. 5C). The averaged strych-
nine dose-response yielded a F EC50 of 458 13 nM, an nH of
2.1  0.1, and a Fmax of 47.0  3.5% (all n  4). Because the
Fmax signals for glycine and strychnine displayed no signifi-
cant difference in sign or size (Fig. 5D), we conclude that the
fluorophore attached to N203C reported identical structural
rearrangements for glycine and strychnine.
The I EC50 for H201C did not change following labeling
with MTS-TAMRA (Table 1). Labeling with MTS-TAMRA
resulted in large F signals (Fig. 5E). The glycine I EC50 was
significantly lower than that of the F signal, whereas nH was
significantly lower for F (Fig. 5, E and F, and Table 1). Inter-
estingly, strychnine produced F signals of the opposite sign
(Fig. 5, G and H), although the small size of the signal (Fmax
1%, n 4) precluded quantitative analysis. To further exam-
ine a possible distinct conformational change, we also labeled
H201C with TMRM and subsequently obtained almost identi-
cal results (Fig. 5, I and J). In contrast to MTS-TAMRA and
TMRM, labeling H201C with AF546 led to an increased fluo-
rescence in response to both glycine and strychnine (Fig. 5K).
However, we found the Fmax for strychnine to be significantly
FIGURE 5. Conformational rearrangements in loop C partially discriminate between glycine and strychnine. A, glycine-induced current (black) and
fluorescence (red) traces recorded from oocytes injected with N203C. B, averaged dose-response relationships for glycine (gly). C, strychnine-induced current
(black) and fluorescence (red) responses at a saturating strychnine (str) concentration.D, comparison ofmaximal current (gray) andmaximal fluorescence (red)
responses for N203C. E, glycine-induced current (black) and fluorescence (red) traces recorded from oocytes injected with H201C. F, averaged dose-response
relationships for glycine. G, strychnine-induced current (black) and fluorescence (red) responses at a saturating strychnine concentration. H, comparison of
maximal current (gray) andmaximal fluorescence (red) responses for H201C. Note the broken y axis. I and K, glycine and strychnine induced current (black) and
fluorescence (red) traces recorded from oocytes injected with H201C labeled with TMRM (I) or AF546 (K). J and L, comparison of maximal current (gray) and
maximal fluorescence (red) responses for H201C labeled with TMRM (J) or AF546 (L). The data are normalized to the mean glycine values. *, p 0.05.
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(p  0.05) larger than that for glycine (Fmax strychnine 
18.0 1.0% (n 3) versus Fmax glycine 9.4 1.8% (n 3))
(Fig. 5, K and L). Taken together, these results strongly suggest
ligand-specific structural rearrangements at H201C. Further-
more, they also demonstrate that distinct conformational
changes can be displayed by differences in sign or size of the
fluorescence signal. K206C did not exhibit a significant glycine
I EC50 change or a significant F following incubation with
any of the fluorophores.
Pre-M1—We mutated all residues from Glu217 to Met227 to
cysteines, with the exception of Arg218, Tyr222, and Tyr233
because cysteine mutations at these positions preclude the
functional expression of GlyRs.4 The I220C, L224C, I225C, and
Q226C mutations all produced no change in glycine I EC50
and no F signal following incubation with any of the four flu-
orophores. We thus conclude that these residues are not
labeled. In contrast, Q219C was successfully labeled with
MTSR, as demonstrated by the significantly decreased I EC50
after MTSR incubation and the robust glycine-induced
decrease in F (Table 1). The I EC50 was substantially lower
than that of F, whereas nH was significantly higher (Table 1).
Similar results were obtained from E217C, G221C, andM227C
mutants labeled with TMRM, MTS-TAMRA, and AF546,
respectively (Fig. 6A and Table 1). Additionally, nH was signif-
icantly lower for F than for I (Fig. 6B and Table 1). Impor-
tantly, none of these labeled residues in the pre-M1 domain
showed a fluorescence signal in response to application of high
(10 M) strychnine concentrations (n 4 each) (Fig. 6C).
Loop 2—Loop 2, which is directly connected to loop D in the
inner -sheet, has previously been implicated in channel gating
in GlyRs and nAChRs (5, 46). In an attempt to investigate
ligand-induced conformational changes in this domain, we cre-
ated the following cysteinemutants: A52C, E53C, T54C, T55C,
andM56C. TheA52Cmutation resulted in a receptor withwild
type-like electrophysiological properties, and labeling with
MTS-TAMRA had no effect on the current EC50. However, it
exhibited a robust decrease in fluorescence in response to gly-
cine application (Table 1 and Fig. 6A). Again, the I EC50 was
significantly lower than that ofF (Fig. 6B and Table 1). Similar
to the situation in the pre-M1 domain, even high (10 M) con-
centrations of strychnine failed to elicit detectable changes in
fluorescence (n  4) (Fig. 6C). The E53C and T54C mutants
both showed significantly smaller maximal currents (Imax 
4.0 0.2 A, n 3 and Imax 4.1 0.3 A, n 3), and there
was no evidence of labeling with any of the dyes, as indicated by
the lack of change in current EC50 and lack of F after the4 S. T. Nevin and J. W. Lynch, unpublished results.
FIGURE 6. Loop 2 and the pre-M1 domain undergo conformational changes in response to glycine application, but not to strychnine application.
A, glycine-induced current (black) and fluorescence (red) traces recorded from oocytes injected with M227C (upper panel) or A52C (lower panel). B, averaged
dose-response relationships for glycine (gly). C, strychnine-induced current (black) and fluorescence (red) responses at a high strychnine (str) concentration.
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labeling procedure (data not shown). Because the T55C and
M56C mutants generated only very small (0.5 A, n 3–4)
currents, they were not further analyzed.
DISCUSSION
General Considerations—Several factors must be taken into
account when interpreting data from VCF studies. First, the
absence of a measurable F does not preclude the possibility of
a conformational change taking place. In fact, a fluorophore
may move a considerable distance between two distinct states
of the receptor, but if the local environment does not change
sufficiently, a F will not be observed. Similarly, we make the
assumption that identical fluorescence changes report similar
changes in hydrophobicity. We acknowledge, however, that an
identical change in fluorescence for two ligands could also
report a different conformational change, because distinct con-
formations may expose the fluorophore to similarly hydropho-
bic environments. Additionally, because of the size of the flu-
orophore and the length of the linker, it is possible that theF is
reporting on a conformational change that occurs at some dis-
tance from labeled site, whereas the site itself remains station-
ary. Where possible, we attempted to overcome these compli-
cations by labeling multiple residues in a given domain. We
reasoned that if multiple positions in a domain report similar
changes, more generalized conclusions could be drawn about
the role of that domain. Furthermore, an observed F may
report on an electrophysiologically silent conformational
change. Finally, as discussed in more detail below, the F can
report on more than one conformational change, and it may
thus be difficult to separate conformational changes associated
with activation from those associated with desensitization.
Because of these limitations, we focus on differences (or simi-
larities) in the sign and/or size of the F signals produced by
agonists and antagonists.
Desensitization—Because of the slow rate of agonist applica-
tion when working with ligand-gated ion channels in the Xeno-
pus expression system, it may be difficult to discriminate
between a F associated with channel activation and a F
evoked by another event, such as desensitization. Thus, in prin-
ciple, an observedFmight be due to a transition from a closed
to a desensitized or from an open to a desensitized state. In fact,
the large number of residues in this study showing a dramati-
cally higher EC50 (and lower nH) for fluorescence than for cur-
rent may suggest that they detect a conformational change
associated with desensitization. Consequently, we will consider
the possibility that F signals may reflect desensitized states in
the following discussion.
Inner -Sheet—Because recent structural studies (22, 23)
showed that receptor activation is accompanied by rearrange-
ments of the entire inner -sheet, we sought to detect these
movements by fluorescently labeling various positions in the
inner -sheet.
The labeled L127C residue exhibits overlapping glycine F
and I concentration-response relations. Furthermore, the
magnitude of the Fmax signals is strongly ligand-dependent,
indicating that glycine and strychnine induce distinct structural
rearrangements at L127C. This finding is supported by a spec-
troscopic analysis of the fluorescence signal, which showed a
blue shift in the emission spectrum for strychnine but not for
glycine. The overlapping I and F dose-response curves sug-
gest that this residue senses a conformational change associ-
ated with the open channel state. Thus, both lines of evidence
support a role for loop E in activation. Such a conclusion would
agree with recent structural data showing large conformational
changes in this domain during activation (22, 23). It also agrees
well with previous VCF studies. The fluorescence recorded
from equivalent or nearby loop E residues in the GABAA and
the GABAC receptors (27, 30) also displayed overlapping gly-
cine F and I concentration responses, and the F signals
were different for agonists and antagonists. A role for loop E in
receptor activation is also supported by single channel kinetic
analyses in the nAChR (50, 51).
Our results from loop D also suggest distinct structural
rearrangements in response to glycine and strychnine. A
recent study using site-directed mutagenesis and modeling
had suggested distinct conformations for agonist and antag-
onist binding at the GlyR Arg65 residue in loop D (36), but
direct experimental evidence was lacking. Here, we report
highly ligand-specific conformational changes at the adjacent
Gln67 position. Additionally, we demonstrate that loop 2
(which is directly connected to loopD and also part of the inner
-sheet) detects a glycine-induced conformational change but
seems to remain stationary when strychnine is bound. A num-
ber of studies have previously provided evidence for a network
of salt bridges connecting the LBD and the M2-M3 linker
region via loop 2 (43, 46, 52–55). Given the close physical prox-
imity of loop 2 to the M2-M3 linker of the transmembrane
domain, which also moves in response to agonists but not
antagonists in both GlyRs and GABAA receptors (31, 32), the
conformational change we detect in loop 2 may reflect an acti-
vated or desensitized state. Taken together, these findings
emphasize the crucial role of the inner -sheet in ligand recog-
nition and, more importantly, in ligand discrimination.
Loop F—The labeled loop F residues, V178C and G181C,
showed no discrimination between binding of glycine and
strychnine. This is a somewhat surprising finding, given the
close proximity to the binding site and the substantial size dif-
ference between glycine and strychnine. However, it is consist-
ent with earlier observations that the relatively large structural
rearrangements in the AChBP loop F occur in response to both
agonist and antagonist binding (11) and that the loop F domain
of serotonin type 3 receptors (20) undergoes ligand-induced
rearrangements that do not necessarily discriminate between
agonists and antagonists. Additionally, a recent VCF study on
the GABAC loop F has found identical F responses for both
agonists and antagonists at T218C, a residue that corresponds
to V178C in the GlyR (21). It is thus conceivable that loop F, as
recently suggested by others (19), plays a major role in ligand
docking, but not necessarily in receptor activation.
Loop C—Our data suggest that loop C undergoes structural
rearrangements in response to ligand binding, in agreement
with structural (6, 7, 9, 11, 42) and computational modeling
studies (14–18). Interestingly, a VCF study on a the GABAC
loop C also observed conformational changes in response to
both agonists and antagonists (27). However, the maximum
signal amplitudes could not be determined, making a direct
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comparison between agonist and antagonist-induced move-
ments difficult (27).
Similar to the situation in loop F, N203C displayed identical
fluorescence changes in response to agonist and antagonist
binding. This is an important finding, because a previous
AChBP crystallographic study has suggested that loop C glo-
bally distinguishes between agonists and antagonists (11).
However, consistent with the findings of that study, we found
that the labeled H201C GlyR responded differently to glycine
and strychnine. For example, TMRM andMTS-TAMRA labels
both yielded increases in F upon glycine binding but reduc-
tions inF upon strychnine binding. In contrast, AF546 yielded
an increased F upon the binding of both strychnine and gly-
cine, although the strychnineFwas significantly larger.More-
over, Lys200 and Tyr202 are among the few residues in the GlyR-
binding site whose orientation differs markedly between
glycine binding and strychnine binding (36, 44). Hence it is not
surprising that fluorophores attached to H201C recognize
these ligand-specific movements. The fact that fluorophores
attached to the nearby N203C do not respond differently to
glycine and strychnine binding is an example for the high spa-
tial resolution of VCF.
Another interesting aspect of our results from loop C is the
fluorophore-dependent F in response to strychnine applica-
tion. A possible explanation for this result is the different linker
length between fluorophore and cysteine side chain for the flu-
orophores used here. Linker lengths are likely to be 5, 7.8, 7.8,
and 15.1 Å for TMRM, MTSR, MTS-TAMRA, and AF546,
respectively (30). Thus, because the AF546 linker is substan-
tially longer than those of TMRM andMTS-TAMRA, we spec-
ulate that it senses a different change in environment upon
strychnine binding.
In conclusion, our results emphasize that loop C does dis-
criminate between agonists and antagonists, although not over
its entire length. Given the importance of loop C for ligand
binding and possibly channel activation in Cys loop receptors,
our findings offer insight into the allosteric mechanisms of this
crucial domain.
Pre-M1Domain—Other studies inferred a crucial role for the
pre-M1 domain based on state-dependent changes in the
strength of electrostatic interactions between oppositely
charged residues in the pre-M1 domain and LBD loops 1-2
or 6-7 (43, 56). However, recent crystal structures of bacte-
rial Cys loop receptors suggested only a minimal movement of
the pre-M1 domain during transition from closed to open (22,
23). Here, we clearly identified agonist-induced structural rear-
rangements in the pre-M1 domain. On the other hand, we
found no evidence for strychnine-induced conformational
changes at any of the four labeled pre-M1 domain residues.
Because glycine opens the channel, whereas strychnine does
not, it seems reasonable to conclude that the pre-M1 domain
senses a conformational change associated with either an acti-
vated or desensitized state.
A Direct Ligand-Fluorophore Interaction?—Theoretically,
the ligand-mediated F responses observed here could origi-
nate from direct quenching or dequenching induced by the
binding of ligands near the fluorophore. Based on the following
arguments, we consider this scenario unlikely. First, a direct
ligand-fluorophore interaction would produce a F at concen-
trations lower than those required for channel activation,
because GlyR require two to three bound glycine molecules to
open (47, 48). This was not the case; at L127C current and
fluorescence were superimposed at low concentrations, and at
all other sitesFwas significantly right-shifted. Second, in loop
F the Fmax values were identical for structurally very different
ligands (e.g. glycine and strychnine at V178C and G181C).
Third, agonists and antagonists have previously been shown to
exert no influence on fluorophores tethered close to the bind-
ing sites of other Cys loop receptors (19, 21, 27, 30, 32). Addi-
tionally, direct ligand-fluorophore interactions seem particu-
larly unlikely in loop 2 and in the pre-M1domain, because these
domains are physically distant from the ligand-binding site.
Taken together, these observations are not compatible with a
ligand-induced quench or dequench of any residue investigated
here.
Conclusion—In this study we identified through fluorophore
labeling 12 residues in the GlyR LBD that sense conformational
changes upon ligand binding. More importantly, we demon-
strate that eight of these residues show ligand-specific confor-
mational changes, discriminating between the agonist glycine
and the competitive antagonist strychnine. Four aspects are
particularly noteworthy: 1) the competitive antagonist strych-
nine induces conformational changes near the binding site only
and not at the interface with the transmembrane domain; 2)
one residue in loopCdiscriminates between glycine and strych-
nine, whereas another does not; these findings indicate that
loopC is important for liganddiscrimination, althoughnot over
its entire length; 3) three residues in the inner -sheet discrim-
inate between agonists and antagonists, underlining the crucial
role of this domain in agonist-specific actions; 4) loop F,
although in close physical proximity to the binding site, does
not discriminate between agonists and antagonists. Thus, loop
F may sense conformational changes that are not essential for
activation. Taken together, these results shed new light on the
conformational variability of the GlyR LBD and extend our
knowledge about the allosteric mechanisms involved in Cys
loop receptor function.
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